Eli Lilly has reported new phase 3 results showing greater average weight loss with investigational retatrutide than with injectable Ozempic 2 mg in adults with type 2 diabetes. The announcement, published on October 28, 2026, is promising, but it does not mean retatrutide is approved or that every patient will achieve the same results. [1] [3]
Watch the interview
In this Spanish-language interview on En Foco con Lourdes del Río, Dr. Yanet Garcia-Brito, DNP, FNP-BC, discusses retatrutide, metabolic health and questions about emerging weight-management medicines. The full video is presented alongside the source-based update below.
Video: approximately 8:42. Original audio in Spanish; Spanish captions available.
Context for viewers: The interview discusses more than one study. Its figures should not be treated as results from a single trial. Retatrutide is one investigational molecule that activates three hormone receptors—not a vaccine and not a mixture of Ozempic and other medicines. The 2023 phase 2 study reporting 24.2% weight loss at 48 weeks compared retatrutide with placebo, not semaglutide or tirzepatide. The head-to-head study described below involved adults with type 2 diabetes and reported different results at 80 weeks. [1] [4]
The video's discussion of nutrition should not be interpreted as showing that these medicines have no adverse effects, or that every symptom is caused only by insufficient nutrients. Adverse events were reported in the retatrutide trial. Hair loss is also listed in the FDA-approved Zepbound prescribing information; that finding concerns tirzepatide and cannot automatically be assigned to retatrutide. [1] [5]
What was tested?
TRANSCEND-T2D-2 was a randomized, open-label phase 3 trial comparing weekly retatrutide with weekly injectable semaglutide, marketed as Ozempic, at 2 mg. Lilly reported 1,298 participants with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Their average starting weight was 225.8 pounds. The reported comparison covers 80 weeks. [1]
The trial's ClinicalTrials.gov identifier is NCT06260722. The registry's September update still lists an estimated enrollment of 1,250, so the final participant count above is attributed to Lilly's announcement. [1] [2]
How much weight did participants lose?
Lilly reported the following average reductions at 80 weeks: [1]
- Retatrutide 9 mg: 44.3 pounds, or 19.5% of starting body weight.
- Retatrutide 12 mg: 47.4 pounds, or 20.9% of starting body weight.
- Ozempic 2 mg: 20.9 pounds, or 9.4% of starting body weight.
These findings support the statement that average weight loss with retatrutide was more than double that with Ozempic 2 mg in this study and analysis. The doses identify the trial groups; they are not prescribing instructions. [1]
The figures use an “efficacy estimand”: an analysis estimating what would happen if participants stayed on the study intervention for 80 weeks without starting additional blood-sugar medication, while allowing certain dose interruptions or modifications. They are not a guarantee for an individual patient or an estimate of outcomes regardless of treatment discontinuation. [1]
What about blood sugar and heart health?
Average A1C—the measure of longer-term blood-sugar control—fell by 2.2 percentage points in both retatrutide groups, compared with 1.8 percentage points with Ozempic. Average A1C at the start was 8.3%. [1]
Lilly also reported greater improvements in non-HDL cholesterol, triglycerides and systolic blood pressure. These are cardiovascular risk factors. This announcement does not establish that retatrutide prevents more heart attacks, strokes or cardiovascular deaths than Ozempic. The release did not give the size of those cholesterol or blood-pressure changes. [1]
What are the safety findings and limitations?
Commonly reported adverse events included diarrhea, nausea, constipation, vomiting and indigestion. Treatment discontinuation because of adverse events occurred in 4.8% of participants in the retatrutide 9 mg group, 7.9% in the 12 mg group and 2.7% with Ozempic. Most of the listed events were mild to moderate, according to Lilly, but that does not make treatment risk-free. [1]
These are topline results released by the manufacturer. Lilly said detailed results would be presented at a future medical meeting and published in a peer-reviewed journal. The announcement is not a substitute for that full report or for longer-term safety assessment. [1]
This comparison is specifically against Ozempic 2 mg in adults with type 2 diabetes. It is not a comparison with every semaglutide formulation, with Wegovy or with tirzepatide. Nor does it establish the same weight loss, prevention of diabetes or reversal of liver disease in people without diabetes. [1] [2]
Is retatrutide available?
As of this November 20, 2026 update, retatrutide remains investigational and is not FDA-approved. The FDA states that it is not a component of an approved drug and cannot be used in compounding under federal law. It should not be presented as an available prescription treatment or purchased as a “research peptide” for personal use. [3]
This article is educational and does not announce retatrutide as a service offered by BKB Medical Center. Do not stop, replace or combine prescribed medicines based on a news report. Discuss treatment options with a licensed healthcare professional who can assess your medical history and individual risks.
Frequently asked questions
Is retatrutide the same as Ozempic?
No. Retatrutide is an investigational molecule that activates GIP, GLP-1 and glucagon receptors. Ozempic contains semaglutide. They are different medicines. [1]
Does “more than double” mean everyone will lose twice as much weight?
No. It describes the group averages in the specified 80-week efficacy analysis. Individual results vary, and the analysis does not represent outcomes regardless of discontinuation or additional treatment. [1]
Does this prove retatrutide is better for the heart?
No. Improvements in cholesterol and blood pressure are not the same as evidence of fewer heart attacks, strokes or cardiovascular deaths. Those outcomes require appropriate clinical evidence. [1]
Do these results apply to people without diabetes?
Not directly. This head-to-head trial studied adults with type 2 diabetes. Other populations and trials must be assessed separately. [1] [2]
Can I get retatrutide at BKB Medical Center?
This page does not offer access to retatrutide. It remains investigational and is not FDA-approved. You may discuss your metabolic health and current treatment options with the healthcare team. [3]
Should I switch from Ozempic because of this news?
Do not change prescribed treatment on your own. A news release cannot determine which treatment is appropriate for you. Review benefits, risks and treatment goals with your prescribing professional.
Talk with our team about metabolic health
A medical evaluation can help you discuss your health history, blood-sugar control and weight-management options. It does not include access to investigational retatrutide.
Schedule a Medical EvaluationReferences
- [1] Eli Lilly: TRANSCEND-T2D-2 topline results, October 28, 2026
- [2] ClinicalTrials.gov: TRANSCEND-T2D-2, NCT06260722
- [3] FDA: Concerns with unapproved GLP-1 drugs used for weight loss
- [4] NEJM 2023: Triple-Hormone-Receptor Agonist Retatrutide for Obesity, phase 2 placebo-controlled trial
- [5] FDA 2026: Zepbound prescribing information, adverse reactions section 6.1